优化贝伐珠单抗一线治疗卵巢癌的剂量:PGOG-ov1试验
PGOG-ov1是一项多中心随机临床试验,拟纳入新诊断晚期(FIGO III/IV期)卵巢癌、输卵管癌或原发性腹膜癌患者,比较7.5 mg/kg与15 mg/kg贝伐珠单抗联合化疗及维持治疗(含或不含奥拉帕利)的疗效、安全性和成本效益,主要终点为无进展生存期。
要点
- PGOG-ov1多中心随机试验比较贝伐珠单抗7.5 mg/kg与15 mg/kg一线治疗晚期卵巢癌。
- 患者接受3周期新辅助化疗联合贝伐珠单抗后行间隔减瘤术,按BRCA和HRD状态分层随机入四组。
- 主要终点为无进展生存期,次要终点包括总缓解率、生活质量和安全性。
核心结论
- 该试验预期为优化贝伐珠单抗剂量提供关键见解,可能在不影响疗效的前提下纳入成本效益更优且更安全的治疗方案。
研究设计与样本
- 多中心、随机临床试验,拟纳入新诊断晚期(FIGO III/IV期)卵巢癌、输卵管癌或原发性腹膜癌患者。
- 患者接受3周期含贝伐珠单抗的新辅助化疗,随后行间隔减瘤术,并按BRCA和HRD状态分层随机进入四个治疗组。
主要发现
- 试验尚未报告结果;主要终点为无进展生存期,次要终点包括总缓解率、生活质量和安全性。
- 数据分析聚焦于BRCA和HRD状态对治疗结局影响的亚组评估。
关键数值与推荐
- 辅助治疗阶段贝伐珠单抗剂量为7.5 mg/kg或15 mg/kg,联合化疗。
- 维持治疗持续至多64周,含或不含奥拉帕利。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The management of advanced ovarian cancer has significantly developed with the integration of bevacizumab into standard therapeutic regimens. While the efficacy of bevacizumab has been established in trials such as GOG218, ICON7, and PAOLA-1, there remains a gap in understanding the advantages of the 7.5 mg/kg dose over the 15 mg/kg regimen. This study addresses this gap by evaluating the efficacy, safety, and cost effectiveness of these two dosing strategies, considering the heterogeneity of patient profiles, including BRCA mutation status and homologous recombination deficiency (HRD). This multicenter, randomized clinical trial will recruit patients with newly diagnosed, advanced-stage (FIGO III/IV) ovarian, fallopian tube, or primary peritoneal cancer. Participants will undergo three cycles of neoadjuvant chemotherapy with bevacizumab, followed by interval debulking surgery and randomization into four treatment arms stratified by BRCA and HRD status. Patients will receive either 7.5 mg/kg or 15 mg/kg bevacizumab in combination with chemotherapy during the adjuvant treatment phase and continue with maintenance therapy for up to 64 weeks, with or without the addition of olaparib. The primary endpoint is progression-free survival. The secondary endpoints include the overall response rate, quality of life, and safety profile. Data analysis focuses on subgroup evaluation of the influence of BRCA and HRD status on treatment outcomes. This study is expected to provide critical insights into optimizing bevacizumab dosing, potentially enabling the inclusion of cost-effective and safer treatment protocols without compromising efficacy. TRIAL REGISTRATION: EUCT number: 2023-509659-15-00. Registered on 09.07.2024.
引用
- Ostrowska-Leśko M, Mądry R, Bobiński M, et al. Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial. Trials. 2025. PMID: 40890782. doi:10.1186/s13063-025-09062-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。